Reply to Drs Munkholm and Paludan-Müller's comment on our paper "Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial"

Maria A Nettis^{1

2}, Carmine M Pariante^{1

2}, Valeria Mondelli^{3

4}

Affiliations

¹ King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, UK.
² National Institute for Health Research Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
³ King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, UK. valeria.mondelli@kcl.ac.uk.
⁴ National Institute for Health Research Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, UK. valeria.mondelli@kcl.ac.uk.

Comment

Maria A Nettis et al. Neuropsychopharmacology. 2021 Aug.

. 2021 Aug;46(9):1552-1553.

doi: 10.1038/s41386-021-01042-1. Epub 2021 May 26.

Maria A Nettis^{1

2}, Carmine M Pariante^{1

2}, Valeria Mondelli^{3

4}

¹ King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, UK.
² National Institute for Health Research Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
³ King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, London, UK. valeria.mondelli@kcl.ac.uk.
⁴ National Institute for Health Research Mental Health Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, UK. valeria.mondelli@kcl.ac.uk.

No abstract available

Comment on

Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial.
Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, Worrell C, Enache D, McLaughlin A, Kose M, Sforzini L, Bogdanova A, Cleare A, Young AH, Pariante CM, Mondelli V. Nettis MA, et al. Neuropsychopharmacology. 2021 Apr;46(5):939-948. doi: 10.1038/s41386-020-00948-6. Epub 2021 Jan 28. Neuropsychopharmacology. 2021. PMID: 33504955 Free PMC article. Clinical Trial.
Caution is advised when interpreting subgroup analyses.
Munkholm K, Paludan-Müller AS. Munkholm K, et al. Neuropsychopharmacology. 2021 Aug;46(9):1551. doi: 10.1038/s41386-021-01025-2. Epub 2021 May 4. Neuropsychopharmacology. 2021. PMID: 33947967 Free PMC article. No abstract available.

1. Nettis MA, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology. 2021;46:939–48. doi: 10.1038/s41386-020-00948-6. - DOI - PMC - PubMed
1. Faries D, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34:3–10. doi: 10.1016/S0022-3956(99)00037-0. - DOI - PubMed
1. Husain MI, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol. 2017;31:1166–75. doi: 10.1177/0269881117724352. - DOI - PubMed
1. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–9. doi: 10.1161/01.CIR.0000053730.47739.3C. - DOI - PubMed
1. Osimo EF, et al. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901–9. doi: 10.1016/j.bbi.2020.02.010. - DOI - PMC - PubMed